Immunotherapy for glioma: Getting closer to the clinical arena?

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 641-647

  Finocchiaro, Gaetano ^a   Pellegatta, Serena ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

dendritic cell based immunotherapy; EGFRvIII; ipilimumab

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; IPILIMUMAB; MONOCYTE CHEMOTACTIC PROTEIN 1; OXALIPLATIN; TRANSFORMING GROWTH FACTOR BETA;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOPLASMIC RETICULUM; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MALE; MELANOMA; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 81855175970     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cbb17     Document Type: Review

References (57)

1. Dillman RO, Duma CM, Ellis RA, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009; 32:914-919.
2. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004; 22:4272-4281. (Pubitemid 41185148)
3. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68:5955-5964.
4. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515-5525. (Pubitemid 41060828)
5. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160-4167. (Pubitemid 40791581)
6. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-4729.
7. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 2006; 10:133-146. (Pubitemid 351976185)
8. Hoa N, Ge L, Kuznetsov Y, et al. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol 2010; 185:4793-4803.
9. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009; 29:1-42.
10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280. (Pubitemid 20195640)
11. Vauleon E, Avril T, Collet B, et al. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010; 2010.
12. Kronik N, Kogan Y, Vainstein V, Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 2008; 57:425-439. (Pubitemid 50007307)
13. HeimbergerAB,Sampson JH.Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-oncology 2011; 13:3-13.
14. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-1118.
15. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009; 16:748-754.
16. Omuro AM. What is the relevance of determining EGFR-variant-III status in glioblastomas? Nat Clin Pract Oncol 2008; 5:188-189. (Pubitemid 351493676)
17. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63:6962-6970. (Pubitemid 37322983)
18. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) 2005; 83:917-926. (Pubitemid 41598692)
19. Choi BD, Archer GE, Mitchell DA, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19:713-723.
20. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 2002; 8:3496-3502. (Pubitemid 35340727)
21. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9:4247-4254. (Pubitemid 37204046)
22. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009; 8:2773-2779.
23. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-148. (Pubitemid 39094044)
24. Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011; 364:627-637.
25. Carballido E, Fishman M. Sipuleucel-T: prototype for development of antitumor vaccines. Curr Oncol Rep 2011; 13:112-119.
26. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
27. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
28. Sondak VK, Smalley KS, Kudchadkar R, et al. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-412.
29. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4\+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007; 13:2158-2167. (Pubitemid 46649886)
30. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4\+CD25\+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648. (Pubitemid 46348738)
31. Jordan JT, Sun W, Hussain SF, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008; 57:123-131. (Pubitemid 350043644)
32. Fine JH, Chen P, Mesci A, et al. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res 2010; 70:7102-7113.
33. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61. (Pubitemid 46067386)
34. Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68:4026-4030.
35. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009; 6:e10.
36. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-1103. (Pubitemid 26338628)
37. Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100:1111-1119.
38. Pellegatta S, Poliani PL, Stucchi E, et al. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro-oncology 2010; 12:377-388.
39. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008; 359:539-541.
40. Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol 2011; 103:231-238.
41. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62:3347-3350. (Pubitemid 34651375)
42. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncology 2008; 10:10-18. (Pubitemid 351250896)
43. Miller G. Brain cancer. A viral link to glioblastoma? Science 2009; 323:30-31.
44. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst 2009; 101:488-497.
45. Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in glioblastoma? Clin Cancer Res 2011; 17:4619-4621.
46. Tabatabai G, Weller M. Glioblastoma stem cells. Cell Tissue Res 2011; 343:459-465.
47. Rahman M, Deleyrolle L, Vedam-Mai V, et al. The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 2011; 68:531-545 (discussion 545).
48. Tunici P, Bissola L, Lualdi E, et al. Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer 2004; 3:25.
49. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9:391-403. (Pubitemid 43668737)
50. Pellegatta S, Poliani PL, Corno D, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006; 66:10247-10252. (Pubitemid 44799739)
51. Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27:1734-1740.
52. Hua W, Yao Y, Chu Y, et al. The CD133\+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol 2011; doi:10.1007/s11060-011-0572-y [Epub ahead of print].
53. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncology 2010; 12:1113-1125.
54. Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010; 9:67-78.
55. Wei J, Barr J, Kong LY, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010; 16:461-473.
56. Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011; 6:e16195.
57. Castriconi R, Daga A, Dondero A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 2009; 182:3530-3539.